SAN FRANCISCO (AP) _ FibroGen Inc. (FGEN) on Thursday reported a loss of $45.4 million in its first quarter.
On a per-share basis, the San Francisco-based company said it had a loss of 53 cents.
The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 68 cents per share.
The biotech drug developer posted revenue of $23.9 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $20 million.
FibroGen shares have fallen slightly more than 1% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $45.67, a decrease of 5% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FGEN at https://www.zacks.com/ap/FGEN